Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Oral semaglutide was initiated with a 4-week dose ... 146 mg/dL. Most were on glucose-lowering therapies like metformin (87%) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) (37.5%).

accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity ...